Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4753610 | 1.00 | KMO (1.00) | KMOTSHRSRD5A2NFE2L2HPGD | |
| SCHEMBL31060580 | 1.00 | KMO (1.00) | KMOTSHRSRD5A2NFE2L2HPGD | |
| SCHEMBL21974233 | 1.00 | KMO (1.00) | KMOTSHRSRD5A2NFE2L2HPGD | |
| SCHEMBL15337002 | 1.00 | KMO (1.00) | KMOTSHRSRD5A2NFE2L2HPGD | |
| SCHEMBL16506215 | 0.85 | KMO (0.74) | KMOTSHRMEN1NPC1MAPT | |
| SCHEMBL15319105 | 0.85 | KMO (0.74) | KMOHPGDMEN1NPC1MAPT | |
| SCHEMBL16506378 | 0.85 | KMO (0.74) | KMOTSHRMAPTLTC4S | |
| SCHEMBL16506208 | 0.85 | KMO (0.74) | KMOTSHRMEN1NPC1MAPT | |
| SCHEMBL16506687 | 0.85 | KMO (0.73) | KMOTSHRSRD5A2NFE2L2HPGD | |
| SCHEMBL12327668 | 0.83 | KMO (0.71) | KMOTSHRSRD5A2HPGDPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250345316-A1 | METHODS OF INCREASING LYMPHOCYTE TRAFFICKING TO THE COLON BY STIMULATING RETINOIC ACID RECEPTORS AND ARYL HYDROCARBON RECEPTORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-11-13 | — | — | US | claimed |
| US-12280047-B2 | Treatment of aneurysms | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2025-04-22 | — | — | US | claimed |
| CN-119485512-A | Dynamic bandwidth capacity control for enterprises | 慧与发展有限责任合伙企业 | 2025-02-18 | — | — | CN | claimed |
| CN-114674827-B | Bridge crack detection method based on two-stage deep learning strategy | 兰州交通大学 | 2024-09-20 | — | — | CN | claimed |
| CN-118485425-A | Multi-fault rush-repair and recovery method for power distribution network containing distributed power supply | 华北电力大学（保定） | 2024-08-13 | — | — | CN | claimed |
| CN-117218821-A | Networked prediction and cooperative control method and device for non-signal-control multi-intersection hybrid vehicle group | 清华大学 | 2023-12-12 | — | — | CN | claimed |
| US-20230143415-A1 | TREATMENT OF ANEURYSMS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2023-05-11 | — | — | US | claimed |
| US-11376248-B2 | Treatment of aneurysms | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2022-07-05 | — | — | US | claimed |
| CN-114674827-A | Bridge crack detection method based on two-stage deep learning strategy | 兰州交通大学 | 2022-06-28 | — | — | CN | claimed |
| WO-2007054348-A1 | NOVEL MEDICAMENTS | Ernst-Moritz-Arndt-Universität Greifswald (DE) | 2007-05-18 | — | — | WO | claimed |
| EP-4750039-A1 | IN-NETWORK COMPUTING USING UPF ENHANCEMENT WITH EXPOSURE IN NEXT GENERATION CELLULAR NETWORKS | INTEL Corporation (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12639711-B2 | Transaction processing device, transaction processing method, and program recording medium | TOSHIBA TEC KABUSHIKI KAISHA (JP) | 2026-05-26 | — | — | US | disclosed |
| US-20260136341-A1 | TECHNIQUES FOR DOWNLINK AND UPLINK RESOURCE MAPPING FOR FULL DUPLEX AND NON-CELL DEFINING SYNCHRONIZATION SIGNAL BLOCK | INTEL CORP (US) | 2026-05-14 | — | — | US | disclosed |
| CN-121619335-A | Lightweight end cloud collaborative data acquisition method and system | 岚图汽车科技股份有限公司 | 2026-03-06 | — | — | CN | disclosed |
| CN-121579227-A | Enterprise digital platform data management method and system | 深圳市思普达软件系统有限公司 | 2026-02-27 | — | — | CN | disclosed |
| US-20150057238-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2015-02-26 | — | — | US | disclosed |
| EP-2833879-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI Foundation, Inc. (US) | 2015-02-11 | — | — | EP | disclosed |
| WO-2013151707-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. (US) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013151707-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. (US) | 2013-10-10 | — | — | WO | disclosed |
| WO-2007054348-A1 | NOVEL MEDICAMENTS | Ernst-Moritz-Arndt-Universität Greifswald (DE) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057238-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, AADAT | KMO 1/4885TSHR 4002/4885SRD5A2 1029/4885 |
| US-20230143415-A1 | TREATMENT OF ANEURYSMS | KYNU, HAAO, HCAR2 | KMO 7/4885TSHR 4479/4885SRD5A2 2127/4885 |
| US-20260136341-A1 | TECHNIQUES FOR DOWNLINK AND UPLINK RESOURCE MAPPING FOR FULL DUPLEX AND NON-CELL DEFINING SYNCHRONIZATION SIGNAL BLOCK | SNRPB2, FOSB, SMCHD1 | KMO 3622/4885TSHR 2405/4885SRD5A2 2858/4885 |
| US-12280047-B2 | Treatment of aneurysms | KYNU, HAAO, HCAR2 | KMO 7/4885TSHR 4479/4885SRD5A2 2127/4885 |
| US-11376248-B2 | Treatment of aneurysms | KYNU, HAAO, HCAR2 | KMO 7/4885TSHR 4479/4885SRD5A2 2127/4885 |
| US-12639711-B2 | Transaction processing device, transaction processing method, and program recording medium | TRRAP, TES, TMT1A | KMO 2626/4885TSHR 206/4885SRD5A2 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.